Reduced intensity conditioning for allogeneic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: Where do we stand?

被引：12

作者：

Anderlini, Paolo ^{[1
]}

Champlin, Richard E. ^{[1
]}

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Dept Blood & Marrow Transplantat, Houston, TX 77030 USA

来源：

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2006年 / 12卷 / 06期

关键词：

reduced-intensity conditioning; allogeneic stem cell transplantation;

D O I：

10.1016/j.bbmt.2006.03.013

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Allogeneic stem cell transplantation following myeloablative conditioning in relapsed and refractory Hodgkin lymphoma (HL) has been associated with substantial transplant-related morbidity and mortality, as well as high relapse rates. Despite these problems, a minority of patients have experienced long-term remissions and presumably cure. As in other hematologic malignancies, reduced intensity conditioning (RIC) has now been introduced as an alternative approach. The published experience with RIC in HL patients is reviewed. While early transplant-related morbidity and mortality seem markedly reduced and preliminary data on patient outcome look promising, this remains a challenging area and additional work be needed to clearly define the role of RIC in relapsed and refractory HL. (C) 2006 American Society for Blood and Marrow Transplantation.

引用

页码：599 / 602

页数：4

共 18 条

[1] Long-term results of blood and marrow transplantation for Hodgkin's lymphoma [J].

Akpek, G ;

Ambinder, RF ;

Piantadosi, S ;

Abrams, RA ;

Brodsky, RA ;

Vogelsang, GB ;

Zahurak, ML ;

Fuller, D ;

Miller, CB ;

Noga, SJ ;

Fuchs, E ;

Flinn, IW ;

O'Donnell, P ;

Seifter, EJ ;

Mann, RB ;

Jones, RJ .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (23) :4314-4321

[2] Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma:: Results of a Spanish prospective cooperative protocol [J].

Alvarez, I ;

Sureda, A ;

Caballero, MD ;

Urbano-Ispizzua, A ;

Ribera, JM ;

Canales, M ;

García-Conde, J ;

Sanz, G ;

Arranz, R ;

Bernal, MT ;

de la Serna, J ;

Díez, JL ;

Moraleda, JM ;

Rubió-Félix, D ;

Xicoy, B ;

Martínez, C ;

Mateos, MV ;

Sierra, J .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (02) :172-183

[3] Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen [J].

Anderlini, P ;

Saliba, R ;

Acholonu, S ;

Okoroji, GJ ;

Donato, M ;

Giralt, S ;

Andersson, B ;

Ueno, NT ;

Khouri, I ;

De Lima, M ;

Hosing, C ;

Cohen, A ;

Ippoliti, C ;

Romaguera, J ;

Rodriguez, MA ;

Pro, B ;

Fayad, L ;

Goy, A ;

Younes, A ;

Champlin, RE .

BONE MARROW TRANSPLANTATION, 2005, 35 (10) :943-951

[4] Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+cell dose, GVHD and disease response [J].

Anderlini, P ;

Acholonu, SA ;

Okoroji, GJ ;

Andersson, BS ;

Couriel, DR ;

De Lima, MJ ;

Donato, ML ;

Khouri, IF ;

Giralt, SA ;

Ueno, NT ;

Champlin, RE .

BONE MARROW TRANSPLANTATION, 2004, 34 (06) :511-514

[5] ALLOGENEIC, SYNGENEIC, AND AUTOLOGOUS MARROW TRANSPLANTATION FOR HODGKINS-DISEASE - THE 21-YEAR SEATTLE EXPERIENCE [J].

ANDERSON, JE ;

LITZOW, MR ;

APPELBAUM, FR ;

SCHOCH, G ;

FISHER, LD ;

BUCKNER, CD ;

PETERSEN, FB ;

CRAWFORD, SW ;

PRESS, OW ;

SANDERS, JE ;

BENSINGER, WI ;

MARTIN, PJ ;

STORB, R ;

SULLIVAN, KM ;

HANSEN, JA ;

THOMAS, ED .

JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (12) :2342-2350

[6] HLA-matched related (MRD) or unrelated donor (URD) non-myeloablative conditioning and hematopoietic cell transplant (HCT) for patients with advanced Hodgkin disease (HD) [J].

Burroughs, LM ;

Maris, MB ;

Sandmaier, BM ;

Leisenring, W ;

Stuart, MJ ;

Niederwieser, D ;

McSweeney, PA ;

Chauncey, T ;

Maziarz, R ;

Agura, E ;

Little, MT ;

Blume, KG ;

Storb, R ;

Maloney, DG .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2004, 10 (02) :73-74

[7] Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma [J].

Carella, AM ;

Cavaliere, M ;

Lerma, E ;

Ferrara, R ;

Tedeschi, L ;

Romanelli, A ;

Vinci, M ;

Pinotti, G ;

Lambelet, P ;

Loni, C ;

Verdiani, S ;

De Stefano, F ;

Valbonesi, M ;

Corsetti, MT .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (23) :3918-3924

[8] Allogeneic hematopoietic transplantation as adoptive immunotherapy - Induction of graft-versus-malignancy as primary therapy [J].

Champlin, R ;

Khouri, I ;

Kornblau, S ;

Marini, F ;

Anderlini, P ;

Ueno, NT ;

Molldrem, J ;

Giralt, S .

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1999, 13 (05) :1041-+

[9] Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease [J].

Gajewski, JL ;

Phillips, GL ;

Sobocinski, KA ;

Armitage, JO ;

Gale, RP ;

Champlin, RE ;

Herzig, RH ;

Hurd, DD ;

Jagannath, S ;

Klein, JP ;

Lazarus, HM ;

McCarthy, PL ;

Pavlovsky, S ;

Petersen, FB ;

Rowlings, PA ;

Russell, JA ;

Silver, SM ;

Vose, JM ;

Wiernik, PH ;

Bortin, MM ;

Horowitz, MM .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (02) :572-578

[10] DOSE INTENSIFICATION WITH AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN RELAPSED AND RESISTANT HODGKINS-DISEASE - RESULTS OF A BNLI RANDOMIZED TRIAL [J].

LINCH, DC ;

WINFIELD, D ;

GOLDSTONE, AH ;

MOIR, D ;

HANCOCK, B ;

MCMILLAN, A ;

CHOPRA, R ;

MILLIGAN, D ;

HUDSON, GV .

LANCET, 1993, 341 (8852) :1051-1054

← 1 2 →